Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Exercise-induced alterations in phospholipid hydrolysis, airway surfactant, and eicosanoids and their role in airway hyperresponsiveness in asthma.

Tytuł:
Exercise-induced alterations in phospholipid hydrolysis, airway surfactant, and eicosanoids and their role in airway hyperresponsiveness in asthma.
Autorzy:
Murphy RC; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington.; Center for Lung Biology, University of Washington, Seattle, Washington.
Lai Y; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington.; Center for Lung Biology, University of Washington, Seattle, Washington.
Nolin JD; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington.; Center for Lung Biology, University of Washington, Seattle, Washington.
Aguillon Prada RA; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio.; Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio.
Chakrabarti A; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio.; Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio.
Novotny MV; Department of Critical Care, Cleveland Clinic, Cleveland, Ohio.; Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio.
Seeds MC; Section on Molecular Medicine, Wake Forest University, Winston-Salem, North Carolina.
Altemeier WA; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington.; Center for Lung Biology, University of Washington, Seattle, Washington.
Gelb MH; Department of Chemistry, University of Washington, Seattle, Washington.; Department of Biochemistry, University of Washington, Seattle, Washington.
Hite RD; Division of Pulmonary Disease & Critical Care Medicine, Department of Medicine, University of Cincinnati, Cincinnati, Ohio.
Hallstrand TS; Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington.; Center for Lung Biology, University of Washington, Seattle, Washington.
Źródło:
American journal of physiology. Lung cellular and molecular physiology [Am J Physiol Lung Cell Mol Physiol] 2021 May 01; Vol. 320 (5), pp. L705-L714. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: Bethesda, MD : American Physiological Society, c1989-
MeSH Terms:
Exercise*
Asthma/*complications
Eicosanoids/*metabolism
Group X Phospholipases A2/*metabolism
Phospholipids/*metabolism
Respiratory Hypersensitivity/*etiology
Surface-Active Agents/*metabolism
Adolescent ; Adult ; Bronchoconstriction ; Female ; Humans ; Hydrolysis ; Male ; Osmotic Pressure ; Respiratory Hypersensitivity/metabolism ; Respiratory Hypersensitivity/pathology ; Sputum ; Young Adult
References:
J Allergy Clin Immunol. 2007 Apr;119(4):838-47. (PMID: 17321580)
Eur Respir J. 2018 Nov 15;52(5):. (PMID: 30361249)
Am J Respir Crit Care Med. 2000 Jan;161(1):309-29. (PMID: 10619836)
Clin Exp Allergy. 2011 Jun;41(6):801-10. (PMID: 21255140)
J Pediatr. 2002 Sep;141(3):343-8. (PMID: 12219053)
J Biol Chem. 1999 Oct 29;274(44):31435-44. (PMID: 10531345)
J Allergy Clin Immunol. 1984 May;73(5 Pt 2):660-5. (PMID: 6715730)
J Biol Chem. 2002 Dec 13;277(50):48535-49. (PMID: 12359733)
Methods Mol Med. 2005;107:183-206. (PMID: 15492373)
N Engl J Med. 2017 May 18;376(20):1911-1920. (PMID: 28514613)
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):827-837. (PMID: 30529275)
Eur Respir J. 2017 May 1;49(5):. (PMID: 28461290)
Med Sci Sports Exerc. 2005 Jun;37(6):904-14. (PMID: 15947713)
Am J Respir Crit Care Med. 2005 Sep 15;172(6):679-86. (PMID: 15947280)
J Biol Chem. 1999 Nov 26;274(48):34203-11. (PMID: 10567392)
Eur Respir J. 2020 Jul 2;56(1):. (PMID: 32299856)
Proc Natl Acad Sci U S A. 2009 May 19;106(20):8296-301. (PMID: 19416808)
J Allergy Clin Immunol. 2014 May;133(5):1448-55. (PMID: 24220317)
Respir Res. 2002;3:4. (PMID: 11806839)
Am J Respir Crit Care Med. 2013 Jul 1;188(1):42-50. (PMID: 23614662)
Am J Respir Crit Care Med. 2007 Dec 1;176(11):1072-8. (PMID: 17901411)
Am J Respir Cell Mol Biol. 2020 Oct;63(4):543-545. (PMID: 32484733)
J Clin Invest. 2002 May;109(10):1373-80. (PMID: 12021253)
Ann Allergy Asthma Immunol. 2009 Sep;103(3):225-32. (PMID: 19788020)
Am J Respir Crit Care Med. 1999 Jun;159(6):1819-23. (PMID: 10351925)
Chest. 2010 Aug;138(2 Suppl):25S-30S. (PMID: 20668015)
Eur Respir J. 2003 Sep;22(3):491-6. (PMID: 14516140)
J Allergy Clin Immunol. 2003 Jun;111(6):1205-11. (PMID: 12789218)
J Magn Reson Imaging. 2014 May;39(5):1230-7. (PMID: 24006239)
Eur Respir J. 2005 Aug;26(2):319-38. (PMID: 16055882)
Eur Respir J. 1995 May;8(5):742-51. (PMID: 7656945)
Swiss Med Wkly. 2013 Jul 29;143:w13818. (PMID: 23896983)
Lipids. 1970 May;5(5):494-6. (PMID: 5483450)
Am J Physiol. 1998 Oct;275(4):L740-7. (PMID: 9755106)
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1784-90. (PMID: 8520737)
Curr Allergy Asthma Rep. 2009 Jan;9(1):18-25. (PMID: 19063820)
Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L618-24. (PMID: 15516491)
J Immunol. 1982 Oct;129(4):1627-31. (PMID: 6809826)
J Immunol. 1984 Apr;132(4):1972-9. (PMID: 6199420)
Immunol Allergy Clin North Am. 2013 Aug;33(3):313-28, vii. (PMID: 23830127)
Pulm Pharmacol Ther. 2012 Dec;25(6):432-7. (PMID: 23323271)
J Exp Med. 2017 Jan;214(1):27-37. (PMID: 28011865)
Grant Information:
K24 AI130263 United States AI NIAID NIH HHS; R01 HL089215 United States HL NHLBI NIH HHS; K24AI130263 HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID); R01HL089215 HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
Contributed Indexing:
Keywords: airway hyperresponsiveness; asthma; eicosanoid; phospholipase A2; surfactant
Substance Nomenclature:
0 (Eicosanoids)
0 (Phospholipids)
0 (Surface-Active Agents)
EC 3.1.1.4 (Group X Phospholipases A2)
EC 3.1.1.4 (PLA2G10 protein, human)
Entry Date(s):
Date Created: 20210203 Date Completed: 20210511 Latest Revision: 20220503
Update Code:
20240105
PubMed Central ID:
PMC8174822
DOI:
10.1152/ajplung.00546.2020
PMID:
33533300
Czasopismo naukowe
The mechanisms responsible for driving endogenous airway hyperresponsiveness (AHR) in the form of exercise-induced bronchoconstriction (EIB) are not fully understood. We examined alterations in airway phospholipid hydrolysis, surfactant degradation, and lipid mediator release in relation to AHR severity and changes induced by exercise challenge. Paired induced sputum ( n = 18) and bronchoalveolar lavage (BAL) fluid ( n = 11) were obtained before and after exercise challenge in asthmatic subjects. Samples were analyzed for phospholipid structure, surfactant function, and levels of eicosanoids and secreted phospholipase A 2 group 10 (sPLA 2 -X). A primary epithelial cell culture model was used to model effects of osmotic stress on sPLA 2 -X. Exercise challenge resulted in increased surfactant degradation, phospholipase activity, and eicosanoid production in sputum samples of all patients. Subjects with EIB had higher levels of surfactant degradation and phospholipase activity in BAL fluid. Higher basal sputum levels of cysteinyl leukotrienes (CysLTs) and prostaglandin D 2 (PGD 2 ) were associated with direct AHR, and both the postexercise and absolute change in CysLTs and PGD 2 levels were associated with EIB severity. Surfactant function either was abnormal at baseline or became abnormal after exercise challenge. Baseline levels of sPLA 2 -X in sputum and the absolute change in amount of sPLA 2 -X with exercise were positively correlated with EIB severity. Osmotic stress ex vivo resulted in movement of water and release of sPLA 2 -X to the apical surface. In summary, exercise challenge promotes changes in phospholipid structure and eicosanoid release in asthma, providing two mechanisms that promote bronchoconstriction, particularly in individuals with EIB who have higher basal levels of phospholipid turnover.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies